louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04553055: Antibiotic Misuse During COVID-19 Pandemic
Official title: Assessment of Community Pharmacies Related Antibiotic Misuse and Application of Infection Control Measures During COVID-19 Pandemic
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Covid19
Keywords: coronavirus
observational survey
antibiotics
Egypt
Lead sponsor: Beni-Suef University
Sponsor class: OTHER
First posted: 2020-09-17
Enrollment: 413
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: community pharmacists worked during the pandemic and dealt with covid-19 patients inside their pharmacies are welcomed to participate

Brief summary: Evaluating the important role of the community pharmacists in pandemics like covid-19 and to find whether there was a misuse of antibiotics during the pandemic or not and to define the reasons behind this misuse if any present.

Detailed description: Community pharmacy in Egypt is considered as the frontline health care system that is easily and freely accessible by the patients, in this pandemic and due to the current circumstances from closing most general hospitals in front of the public, and with the government applying curfew long hours, community pharmacists were the only healthcare providers available for most patients. Their role will not be restricted to delivering medication but expands to monitoring patient conditions especially those with chronic diseases and patient counseling and education clarifying any misunderstanding concerning covid1-19 medication. The present study includes a questionnaire (with detailed questions including how/when/which/for how long antibiotics are prescribed) that is addressed for community pharmacists who dealt with covid-19 patients during the pandemic.

Eligibility criteria: Inclusion Criteria:

* All community pharmacists worked during the pandemic and dealt with covid-19 patients inside their pharmacies are welcomed to participate

Exclusion Criteria:

* Clinical and hospital pharmacists- other medical staff- pharmacist assistant

Primary outcomes:
measure: antibiotic misuse
timeFrame: 15-20 days
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: BeniSuefU
state: BeniSuef
Study officials:
affiliation: lecturer
name: Hoda M Rabie, PHD
role: STUDY_CHAIR
References:
Clinical trial NCT00675155: Far Infrared Irradiation for Stroke Rehabilitation
Official title: Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Stroke Rehabilitation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Stroke
Keywords: Apoplexy
Cerebral Stroke
Cerebrovascular Accident
Cerebrovascular Accident, Acute
Cerebrovascular Apoplexy
Cerebrovascular Stroke
Lead sponsor: GAAD Medical Research Institute Inc.
Sponsor class: OTHER
First posted: 2008-05-08
Enrollment: 10
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A stroke is a sudden loss of brain function. It is caused by the interruption of flow of blood to the brain (ischemic stroke) or the rupture of blood vessels in the brain (hemorrhagic stroke). This study will investigate the use of far infrared radiation for stroke rehabilitation.

Detailed description: A stroke is a sudden loss of brain function. The interruption of blood flow or the rupture of blood vessels causes brain cells (neurons) in the affected area to die. The effects of a stroke depend on where the brain was injured, as well as how much damage occurred. A stroke can impact any number of areas including your ability to move, see, remember, speak, reason and read and write.

It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people with stroke.

Eligibility criteria: Inclusion Criteria:

* People with Stroke

Exclusion Criteria:

* None

Primary outcomes:
measure: Management and Cure of Stroke
timeFrame: 2 Years
Secondary outcomes:
measure: Rehabilitation of the following: ability to move, see, remember, speak, reason and read and write.
timeFrame: 2 Years
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: The Centre for Incurable Diseases
state: Ontario
Study officials:
affiliation: GAAD Medical Research Institute Inc.
name: Ken Nedd, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02469155: A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
Official title: A Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-Center Study to Assess the Antipsychotic Efficacy of ITI-007 After 6 Weeks of Treatment in Patients With Schizophrenia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Schizophrenia
Lead sponsor: Intra-Cellular Therapies, Inc.
Sponsor class: INDUSTRY
First posted: 2015-06-11
Enrollment: 696
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study will evaluate the antipsychotic efficacy of ITI-007 in a randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation of psychosis.


Eligibility criteria: Inclusion Criteria:

* male or female subjects of any race, ages 18-60 inclusive, with a clinical diagnosis of schizophrenia
* experiencing an acute exacerbation of psychosis

Exclusion Criteria:

* any subject unable to provide informed consent
* any female subject who is pregnant or breast-feeding
* any subject judged to be medically inappropriate for study participation

Primary outcomes:
measure: Positive and Negative Syndrome Scale Total Score
timeFrame: 6 weeks
Secondary outcomes:
measure: Positive and Negative Syndrome Scale Subscales
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Long Beach
country: United States
facility: Clinical Site
state: California
Study officials:
affiliation: Intra-Cellular Therapies, Inc.
name: Kimberly Vanover, Ph.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT02599155: The Effect of the Hydroxyethyl Starch on Kidney Injury in Pediatric Cardiac Surgery
Official title: The Effect of the Hydroxyethyl Starch on Kidney Injury in Pediatric Cardiac Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Kidney Injury
Keywords: crystalloid
colloid
children
infant
cardiac surgery
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2015-11-06
Enrollment: 200
Sex: ALL
Maximum age (years): 7
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The investigator will evaluate the influence of colloid administration on postoperative acute kidney injury in pediatric patients undergoing cardiac surgery under cardiopulmonary bypass.

Detailed description: The investigator will randomly divide pediatric patients aged less than 7 years old into crystalloid and colloid groups. Crystalloid group receive only crystalloid, and colloid group receive hydroxyethyl starch (HES, 130/0.4). The maximum volume of HES is limited less than 30 ml/kg. The same transfusion protocol will be applied in both groups. From the day of operation to postoperative 7 days, glomerular filtration rate (GFR), serum creatinin level (Cr) will be checked. Acute kidney injury (AKI) is defined when there is more than 50% increase in Cr when compared to baseline level. The investigator will compare the clinical outcomes including AKI between two groups.

Eligibility criteria: Inclusion Criteria:

* Children aged less than 7 years old
* American Society of Anesthesiology (ASA) physical status 1-3

Exclusion Criteria:

* Preoperative creatinine \> 1.5mg/dl
* History of dialysis
* Liver function abnormality
* Diabetes Mellitus
* History of allergic reaction
* Coagulation abnormality

Primary outcomes:
measure: Acute Kidney Injury
timeFrame: From the day of surgery to postoperative 7 days
Secondary outcomes:
measure: Blood loss
timeFrame: From the day of surgery to postoperative 7 days
measure: Transfusion amount
timeFrame: From the day of surgery to postoperative 7 days
measure: Mechanical ventilation time
timeFrame: From the day of surgery to postoperative 7 days
measure: Length of ICU stay
timeFrame: From the day of surgery to postoperative 7 days
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul national university hospital
Study officials:
affiliation: Seoul National University Hospital
name: Jin-Tae Kim, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Oh HW, Lee JH, Kim HC, Kim EH, Song IK, Kim HS, Kim JT. The effect of 6% hydroxyethyl starch (130/0.4) on acute kidney injury in paediatric cardiac surgery: a prospective, randomised trial. Anaesthesia. 2018 Feb;73(2):205-215. doi: 10.1111/anae.14129. Epub 2017 Nov 17.
Clinical trial NCT01871155: Effect of Nutri-jelly on Quality of Life in Head and Neck Cancer Patients
Official title: Efficacy Study of Nutri-jelly Intake on Quality of Life in Head and Neck Cancer Patients Undergoing Radiotherapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Head and Neck Cancer
Dysphagia
Lead sponsor: Dental Innovation Foundation Under Royal Patronage
Sponsor class: OTHER
Collaborators: name: Thammasat University
name: Srinakharinwirot University
name: Mahidol University
name: Ministry of Health, Thailand
First posted: 2013-06-06
Enrollment: 64
Sex: ALL
Minimum age (years): 35
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to determine whether a novel edible nutritious gel for patients with chewing and swallowing difficulties, Nutri-jelly, is effective in improving the quality of life of head and neck cancer patients while undergoing conventional radiotherapy.

Detailed description: * independent variable: continuous Nutri -jelly intake
* dependent variable (outcome): changes in health-related quality of life score

Eligibility criteria: Inclusion Criteria:

* diagnosed as head and neck cancer
* definitive or palliative radiotherapy treatment plan
* can communicate well

Exclusion Criteria:

* bleeding in the mouth
* respiratory distress
* psychiatric disorders
* radiation field not involve masticatory and swallowing apparatus e.g. certain cases of laryngeal cancer and brain cancer

Primary outcomes:
measure: Changes in Health-related quality of life score
timeFrame: 0, 1, 2, 3, 4, 5, 6 weeks after radiotherapy
Secondary outcomes:
Other outcomes:
Locations:
city: Pathumthani
country: Thailand
facility: Mahavachiralongkorn cancer hospital
Study officials:
affiliation: Faculty of Dentistry, Thammasat University, Thailand
name: Dunyaporn Trachootham, DDS, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT06609655: AgeTeQ Database Management Framework
Official title: AgeTeQ Database Management Framework "Arts, Health and New Information and Communication Technologies&#34;
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Adults 18 Years and Older (no Other Exclusion Criteria)
Keywords: arts and health
telehealth
Lead sponsor: Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal
Sponsor class: OTHER_GOV
Collaborators: name: Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal
First posted: 2024-09-24
Enrollment: 10000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The bank will be set up within the framework of various research projects of the databank administrator.

Brief summary: The AgeTeQ "Arts, health and new information and communication technologies (NICTs)" laboratory database contains all the clinical and paraclinical data of participants in clinical research projects carried out by the AgeTeQ laboratory on the themes of the arts, and/or health, and/or NICTs.

The database can thus contain quantitative data (i.e. non-invasive measurements taken with questionnaires or measuring devices providing numerical values such as blood pressure, heart rate or electrical activity of the brain, etc.) and qualitative data (i.e. extracted from a verbatim in the context of guided interviews) from participants in the above-mentioned clinical research projects. These data can take the form of spreadsheets containing numerical values, written documents such as verbatims, and audio or video recordings.


Eligibility criteria: Inclusion Criteria:

* Had participate to a previous research project managed by the administrator of the databank
* Agreed to integrated the databank

Exclusion Criteria:

* Less than 18 years old

Primary outcomes:
measure: Preserve the data collected as part of the research projects carried out by the AgeTeQ laboratory
timeFrame: 20 years
measure: Analyze the data collected as part of the research projects carried out by the AgeTeQ laboratory
timeFrame: 20 years
measure: Share the data collected as part of the research projects carried out by the AgeTeQ laboratory
timeFrame: 20 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03624855: Implant-Associated P. Aeruginosa Bone And Joint Infections : Experience In A Regional Reference Center In France
Official title: Implant-Associated P. Aeruginosa Bone And Joint Infections : Experience In A Regional Reference Center In France
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Bone and Joint Infection
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2018-08-10
Enrollment: 94
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients having BJI on implant caused by Pseudomonas aeruginosa managed at the Croix Rousse Hospital

Brief summary: The aim of this study is to describe the bone or joint infection due to Pseudomonas aeruginosa in patients having implant.


Eligibility criteria: Inclusion Criteria:

* patients having BJI on implant caused by Pseudomonas aeruginosa

Exclusion Criteria:

-

Primary outcomes:
measure: Description and rate of bone or joint infection on implant caused due to Pseudomonas aeruginosa
timeFrame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
Secondary outcomes:
measure: Rate of adverse events occurring under medical treatment against Pseudomonas aeruginosa
timeFrame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
measure: Rate of Treatment Failure
timeFrame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
Other outcomes:
Locations:
city: Lyon
country: France
facility: Hospices Civils de Lyon
Study officials:
affiliation: Hospices Civils de Lyon Hôpital de la Croix-Rousse
name: Tristan FERRY, Md,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05096455: Hypertriglyceridemia Associated Acute Pancreatitis in Intensive Care Unit and Therapeutic Plasmapheresis
Official title: Hypertriglyceridemia Associated Acute Pancreatitis in Intensive Care Unit and Therapeutic Plasmapheresis: a Multicenter Retrospective Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pancreatitis
Hypertriglyceridemia
Keywords: ICU
Lead sponsor: Centre Hospitalier Universitaire de Nīmes
Sponsor class: OTHER
First posted: 2021-10-27
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Any patient hospitalized with severe acute pancreatitis of hypertriglycemic origin admitted to the ICU between January 2010 and January 2020.

Brief summary: Acute pancreatitis (AP) is a one of the potentially life-threatening complication of severe hypertriglyceridemia (HTG), with mortality around to 30%.

HTG-associated PA and their complications management has to be the same as the other pancreatitis, but they are associated with the worse clinical outcomes. Triglycerides levels are correlated with the risk of pancreatitis and severity.

Therapeutic plasma exchange (TPE) could provide positive effects in reducing triglyceridemia plasma levels during the acute phase of HTG-AP, and in prevention of recurrence. There is currently no difference about mortality in studies. Some authors have recommended its use only in severe HTG-AP and have precised the need of early initiation to have positive results.

Despite such promising findings from studies, the effects of therapeutic plasma exchange on HTG-associated PA have never been specifically assessed and its benefits in critically ill patients with AP remains uncertain.


Eligibility criteria: Inclusion Criteria:

* Age \> 18 years
* Admission in ICU for acute pancreatitis associated with HTG

Exclusion Criteria : Patient without norepinephrine or missing data.

* Acute pancreatitis without HTG
* Patient already include in this study
* Patient opposed to use of his data

Primary outcomes:
measure: Mortality at Day 28
timeFrame: Day 28
Secondary outcomes:
measure: Length of hospitalization
timeFrame: Day 28
measure: Use of organ support
timeFrame: Day 28
measure: Assess benefit of plasmapheresis
timeFrame: Day 28
Other outcomes:
Locations:
city: Nîmes Cedex 09
country: France
facility: CHU de Nîmes - Hôpital Universitaire Carémeau
Study officials:
affiliation: Centre Hospitalier Universitaire de Nîmes
name: stephanie Bulyez, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02690155: Real-world Comparative Effectiveness of Rivaroxaban Versus VKA
Official title: Real-world Comparative Effectiveness of Rivaroxaban Versus VKA
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Atrial Fibrillation
Keywords: Non-valvular atrial fibrillation (NVAF)
Prevention
Stroke
Lead sponsor: Bayer
Sponsor class: INDUSTRY
Collaborators: name: Janssen Research & Development, LLC
First posted: 2016-02-24
Enrollment: 38831
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with non-valvular atrial fibrillation (NVAF)

Brief summary: To obtain a better understanding on the comparative effectiveness of rivaroxaban versus VKA(Vitamin K antagonist) for stroke prevention in patients with NVAF(non-valvular atrial fibrillation) in a real-life setting


Eligibility criteria: Inclusion Criteria:

* NVAF(non-valvular atrial fibrillation) will be defined as the occurrence of 2 or more inpatient or outpatient claims with ICD(International Classification of Disease)-9 427.31 as the diagnosis code at any time in the patient's data history prior to inclusion
* Patients will be required to have 180 days of enrollment for the assessment of baseline characteristics
* CHA2DS2-Vasc score ≥2 during the 180 days prior to index rivaroxaban use baseline period (CHA2DS2-Vasc: Diabetes mellitus; S2: prior Stroke or TIA or Thromboembolism; V: Vascular disease; A: Age 65-74 years; Sc: Sex category)

Exclusion Criteria:

* Patients \<18 years of age
* Patients with valvular AF (Atrial fibrillation)
* Pregnancy
* Malignant cancers
* Transient cause of AF
* Patients with venous thromboembolism (pulmonary embolism or deep vein thrombosis)
* Patients with major surgery defined as hip or knee replacement
* Prescriptions of oral anticoagulants (OACs) (apixaban, warfarin, dabigatran, rivaroxaban) before index date
* Prescription of more than one OAC on the index date
* Patient with any of the events defined in the composite endpoint

  * Fatal bleeding
  * Fatal Stroke/Myocardial infarction
  * Intracranial hemorrhage
  * Ischemic stroke
  * Myocardial infarction

Primary outcomes:
measure: Incidence of Hospitalization Events (composite endpoint)
timeFrame: Within 2 years of starting treatment
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
state: New York
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT04416555: Virtual Reality Distraction for Reduction
Official title: Virtual Reality Distraction for Reduction in Acute Postoperative Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postoperative Pain
Lead sponsor: The Cleveland Clinic
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2020-06-04
Enrollment: 113
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: parallel assignment (one arm will receive the full immersive virtual reality experience and the other arm will receive a static presentation in the same device)
Primary purpose: SUPPORTIVE_CARE

Brief summary: Using a randomized controlled design, the investigators goal is to estimate the effect of VR on postoperative analgesia and opioid consumption.

Detailed description: Specifically, the investigators propose to test the primary hypothesis that the use of AppliedVR software in Pico G2 4K headsets decreases acute postoperative pain scores (with a 1 point difference considered clinically important) compared to sham treatment on a 0-10 scale 15 minutes after each use in the first 48 hours after surgery or hospital discharge, whichever comes first.

Eligibility criteria: Inclusion Criteria:

* American Society of Anesthesiology Physical Status 1-3;
* Scheduled for elective, primary total hip arthroplasty;
* Anticipated hospitalization of at least 1 night;
* Expected to require parenteral opioids for postoperative pain;
* Able to use IV PCA systems.

Exclusion criteria:

* History of chronic pain or care by a pain management specialist;
* Use of more than 30 mg/day of oral oxycodone (or equivalent);
* Greater than 12 weeks of current and continued opioid use;
* History of seizures, epilepsy, motion sickness, stroke, dementia;
* Non-English speaking;
* Women who are pregnant or breastfeeding;
* History of substance use disorder.

Primary outcomes:
measure: Pain Scores (Numerical Rating Scale)
timeFrame: From the end of surgery until 48 hours after surgery or discharge, whichever comes first
Secondary outcomes:
measure: Total Opioid Consumption
timeFrame: End of surgery to 72 hours after surgery.
measure: Time Weighted Average Pain Score
timeFrame: End of surgery to 48 hours after surgery
measure: Perception of Video System Usability
timeFrame: Once between last intervention time and hospital discharge (up to 8 days after end of surgery)
measure: Post Discharge Analgesia.
timeFrame: One week (7 days) after hospital discharge
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: Cleveland Clinic Fairview Hospital
state: Ohio
Study officials:
affiliation: The Cleveland Clinic
name: Sabry Ayad, MD
role: PRINCIPAL_INVESTIGATOR
References: